About Genzyme
Genzyme is a company based in Boston (United States) founded in 1996 was acquired by Sanofi in February 2011. Genzyme has completed 2 acquisitions, including Bioenvision and Ilex Oncology. Genzyme offers products and services including Vaccines, Medicines for Immunology, Neurology Medicines, and Consumer Healthcare Products.
- Headquarter Boston, United States
-
Sectors
Healthcare
-
Phone
Locked
-
Website
Locked
-
Social
Locked
- Legal Name Genzyme India Private Limited
- Date of Incorporation 21 Nov, 2007
- Jurisdiction Mumbai, Maharashtra, India
-
Annual Revenue
$65.35 K (USD)-32.22as on Mar 31, 2017
-
Net Profit
$24.43 K (USD)-23.31as on Mar 31, 2017
-
EBITDA
-$20.73 K (USD)40.38as on Mar 31, 2017
-
Latest Funding Round
Not available
- Investors
-
Employee Count
Not available
-
Investments & Acquisitions
Bioenvision
& 1 more
-
Acquired by
Sanofi
(Feb 16, 2011)
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of Genzyme
Genzyme offers a comprehensive portfolio of products and services, including Vaccines, Medicines for Immunology, Neurology Medicines, and Consumer Healthcare Products.
Products that prevent diseases like influenza and meningitis.
Treatments targeting immune system disorders and related conditions.
Drugs for neurological conditions such as rare diseases and disorders.
Items for allergy, cold relief, and digestive health management.
Funding Insights of Genzyme
Detailed funding history for Genzyme
Round names, dates, amounts, investors, and valuation history require an active premium plan.
- Round names and dates
- Funding amounts
- Participating investors
- Valuation history
Verified entity values are shown only after access is granted.
Investors in Genzyme
Genzyme has secured backing from 1 investor, including institutional investors. Prominent investors backing the company include Sanofi.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Pharmaceutical and nutraceutical products are developed across seven therapeutic areas.
|
Locked | Locked | Locked |
Investor details for Genzyme
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Genzyme
Genzyme has strategically engaged in corporate development activities, having acquired 2 companies. Notable acquisitions include Bioenvision and Ilex Oncology.
Investment portfolio details for Genzyme
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Monoclonal antibody therapies for B-cell chronic lymphocytic leukemia are developed.
|
Locked | Locked | 2000 | Locked | |
|
Acquisition, development, and marketing of compounds and technologies for the treatment of cancer
|
Locked | Locked | 1996 | Locked |
Complete acquisition details for Genzyme
Transaction dates, acquired stakes, disclosed values, domains, and locations require an active premium plan.
- Transaction dates
- Acquired stakes
- Disclosed values
- Domains and locations
Verified entity values are shown only after access is granted.
Financial Statements - Genzyme
Detailed financials for Genzyme
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Genzyme Comparisons
Peer comparison for Genzyme
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Genzyme
Detailed competitors of Genzyme
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Genzyme
Complete news archive for Genzyme
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Genzyme
Genzyme was founded in 1996.
Genzyme is headquartered in Boston, United States. It is registered at Boston, Massachusetts, United States.
Annual revenue of Genzyme is $65.35K as on Mar 31, 2017.
Genzyme Corporation is a fully owned subsidiary of Sanofi. It is focused on rare genetic diseases known as lysosomal storage disorders (LSDs). They have also expanded through both in-house development and strategic acquisitions and partnerships to other disease areas such as thyroid cancer and multiple sclerosis. The first orphan-drug for Genzyme that FDA approved was Ceredase, a drug for treating Gaucher disease. Other important drugs made by Genzyme are Renagel, used in treatment of dialysis patients, and Fabrazyme, used to treat patients with Fabrys disease. Other products in development are Tolevamer for Clostridium difficile colitis and Campath for Chronic lymphocytic leukemia.
Genzyme offers Vaccines, Medicines for Immunology, Neurology Medicines, and Consumer Healthcare Products.
Genzyme has made 2 acquisitions, including Bioenvision, and Ilex Oncology.
Genzyme has 1 investor. Key investors include Sanofi.